000661 长春高新
已收盘 07-03 15:00:00
资讯
新帖
简况
长春高新(000661)披露子公司GenSci164注射液临床试验申请获批公告,7月3日股价下跌0.22%
证券之星 · 07-03 22:50
长春高新(000661)披露子公司GenSci164注射液临床试验申请获批公告,7月3日股价下跌0.22%
长春高新最新公告:子公司GenSci164注射液临床试验申请获批准
证券之星 · 07-03 19:10
长春高新最新公告:子公司GenSci164注射液临床试验申请获批准
长春高新:公司稳步推进生长激素相关产品出海布局
证券之星 · 07-01
长春高新:公司稳步推进生长激素相关产品出海布局
长春高新:公司以经营业绩为市值管理根本
证券之星 · 07-01
长春高新:公司以经营业绩为市值管理根本
股市必读:长春高新(000661)6月30日董秘有最新回复
证券之星 · 07-01
股市必读:长春高新(000661)6月30日董秘有最新回复
6月29日长春高新涨7.88%,创新药ETF银华基金重仓该股
证券之星 · 06-29
6月29日长春高新涨7.88%,创新药ETF银华基金重仓该股
长春高新(000661.SZ)子公司注射用醋酸曲普瑞林(II)获得《药品注册证书》
智通财经 · 06-22
长春高新(000661.SZ)子公司注射用醋酸曲普瑞林(II)获得《药品注册证书》
股市必读:长春高新(000661)6月18日董秘有最新回复
证券之星 · 06-22
股市必读:长春高新(000661)6月18日董秘有最新回复
每周股票复盘:长春高新(000661)现1723.58万元大宗交易
证券之星 · 06-21
每周股票复盘:长春高新(000661)现1723.58万元大宗交易
长春高新:结缔组织病相关间质性肺病相关适应症处于临床阶段
证券之星 · 06-18
长春高新:结缔组织病相关间质性肺病相关适应症处于临床阶段
长春高新:未发现存在违规变相协助大股东化债的情况
证券之星 · 06-18
长春高新:未发现存在违规变相协助大股东化债的情况
长春高新:酒店项目于2025年6—7月相继正式开业运营
证券之星 · 06-18
长春高新:酒店项目于2025年6—7月相继正式开业运营
长春高新:公司经营管理层努力提升经营质量
证券之星 · 06-18
长春高新:公司经营管理层努力提升经营质量
6月15日长春高新现1723.58万元大宗交易
证券之星 · 06-15
6月15日长春高新现1723.58万元大宗交易
长春高新最新公告:子公司注射用GenSci136获临床试验批准
证券之星 · 06-10
长春高新最新公告:子公司注射用GenSci136获临床试验批准
长春高新:系统性推进市值管理工作
证券之星 · 06-10
长春高新:系统性推进市值管理工作
长春高新:公司全力聚焦医药创新与主业发展
证券之星 · 06-10
长春高新:公司全力聚焦医药创新与主业发展
长春高新:产品临床试验获批相关公告是公司为了响应投资者所提出的希望公司持续提升信息披露透明度、增强投资者对于公司在研管线等情况了解的诉求进行的信息披露
证券之星 · 06-10
长春高新:产品临床试验获批相关公告是公司为了响应投资者所提出的希望公司持续提升信息披露透明度、增强投资者对于公司在研管线等情况了解的诉求进行的信息披露
长春高新:公司正处于从单一爆品向多元化创新的研发转型阵痛期
证券之星 · 06-05
长春高新:公司正处于从单一爆品向多元化创新的研发转型阵痛期
长春高新:公司此前向港交所提交的 H 股发行上市申请材料(A1 申请表)已超过港交所规定的六个月申报有效期
证券之星 · 06-05
长春高新:公司此前向港交所提交的 H 股发行上市申请材料(A1 申请表)已超过港交所规定的六个月申报有效期
加载更多
公司概况
公司名称:
长春高新技术产业(集团)股份有限公司
所属行业:
医药制造业
上市日期:
1996-12-18
主营业务:
长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是注射用人生长激素、重组人生长激素注射液、注射用重组人促卵泡激素、重组人促卵泡激素注射液、醋酸曲普瑞林注射液、伏欣奇拜单抗、屋尘螨变应原制剂、醋酸甲地孕酮口服混悬液、口腔凝胶、水痘减毒活疫苗、带状疱疹减毒活疫苗、冻干鼻喷流感减毒活疫苗、鼻喷流感减毒活疫苗、银花泌炎灵片、清胃止痛微丸、血栓心脉宁片、疏清颗粒。
发行价格:
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":68.96,"timestamp":1783062186000,"preClose":69.11,"halted":0,"volume":8128111,"delay":0,"changeRate":-0.0022,"floatShares":400000000,"shares":408000000,"eps":-0.103,"marketStatus":"已收盘","change":-0.15,"latestTime":"07-03 15:00:00","open":69.93,"high":70.38,"low":68.12,"amount":562000000,"amplitude":0.0327,"askPrice":68.96,"askSize":66,"bidPrice":68.95,"bidSize":15,"shortable":0,"etf":0,"ttmEps":-0.103,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"adjPreClose":69.11,"symbolType":"stock","openAndCloseTimeList":[[1783042200000,1783049400000],[1783054800000,1783062000000]],"highLimit":76.02,"lowLimit":62.2,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.27,"roa":"--","roe":"1.25%","epsLYR":0.39,"committee":0.614907,"marketValue":28131000000,"turnoverRate":0.0203,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-07-06。","floatMarketCap":27557000000},"requestUrl":"/m/hq/s/000661","defaultTab":"news","newsList":[{"id":"2648664368","title":"长春高新(000661)披露子公司GenSci164注射液临床试验申请获批公告,7月3日股价下跌0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648664368","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648664368?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:50","pubTimestamp":1783090220,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,长春高新报收于68.96元,较前一交易日下跌0.22%,最新总市值为281.31亿元。该股当日开盘69.93元,最高70.38元,最低68.12元,成交额达5.62亿元,换手率为2.03%。近日,长春高新子公司金赛药业收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,其自主研发的GenSci164注射液获准开展治疗甲状旁腺功能减退症的境内生产药品注册临床试验。目前临床试验审批已获批准,后续进程及结果仍存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300046076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","000661","BK0046","BK0075","BK0057","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648634266","title":"长春高新最新公告:子公司GenSci164注射液临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634266","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648634266?lang=zh_cn&edition=full","pubTime":"2026-07-03 19:10","pubTimestamp":1783077036,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司子公司金赛药业收到国家药监局核准签发的《药物临床试验批准通知书》,GenSci164注射液境内生产药品注册临床试验申请获得批准,拟用于治疗甲状旁腺功能减退症。该药品为金赛药业自主研发的PTH1R激动剂,属于治疗用生物制品1类,依托长效缓释多肽技术Duratide设计,旨在降低给药频率并稳定血钙和血磷水平。但药品研发周期长、风险高,后续进程及结果存在不确定性,投资者需注意风险。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300038845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0057","BK0075","BK0188","BK0046","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515451","title":"长春高新:公司稳步推进生长激素相关产品出海布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648515451?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:27","pubTimestamp":1782894448,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司长效生长激素出海情况如何?长春高新回复:公司稳步推进生长激素相关产品出海布局,同时根据不同国家、地区的行业、市场、政策等,持续挖掘海外市场增量,丰富长期价值增长点。对于具体销售数据情况,请持续关注公司定期报告等列示的相关内容,谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100030909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0188","BK0239","BK0046","BK0028","000661","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515910","title":"长春高新:公司以经营业绩为市值管理根本","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515910","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648515910?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:18","pubTimestamp":1782893900,"startTime":"0","endTime":"0","summary":"公司股价已经到了非常危险的程度 请不要说空话官话来回复投资者长春高新回复:感谢您对公司的关注和建议,我们会将您的意见转达给经营管理层。公司以经营业绩为市值管理根本,一直在努力提升经营质量,加快产品研发、销售力度,筑牢内在价值根基;也将在合规的基础上持续提升资本市场沟通力度,多措并举推动市值真实匹配企业内在价值,提振长期持股信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100030258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0239","BK0188","BK0075","BK0046","BK0057","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648763565","title":"股市必读:长春高新(000661)6月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648763565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648763565?lang=zh_cn&edition=full","pubTime":"2026-07-01 01:58","pubTimestamp":1782842293,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘,长春高新报收于66.6元,下跌1.7%,换手率2.26%,成交量9.04万手,成交额5.99亿元。董秘最新回复投资者: 你好,公司二级市场股价近一年跌超55%,请公司认真考虑股东诉求,尽快安排回购注销,提升市场信心。同时,公司未来若有达到信息披露要求的市值管理相关举措安排,将严格履行决策程序并及时对外披露,谢谢!当日关注点交易信息汇总:6月30日主力资金净流出1889.91万元,游资资金净流入2143.98万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100001116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0239","BK0028","BK0188","BK0075","000661","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647628322","title":"6月29日长春高新涨7.88%,创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647628322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647628322?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:48","pubTimestamp":1782722904,"startTime":"0","endTime":"0","summary":"证券之星消息,6月29日长春高新涨7.88%创60日新低,收盘报67.75元,换手率3.87%,成交量15.48万手,成交额10.24亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0046","BK0028","159316","BK0188","BK0239","000661","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645407460","title":"长春高新(000661.SZ)子公司注射用醋酸曲普瑞林(II)获得《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2645407460","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645407460?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:53","pubTimestamp":1782118419,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)发布公告,近日,公司控股子公司——长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药品注册证书》,金赛药业注射用醋酸曲普瑞林(II)的境内生产药品注册上市许可申请获得批准。该药品适用于体重20kg及以上儿童中枢性性早熟(CPP)治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ)子公司注射用醋酸曲普瑞林(II)获得《药品注册证书》","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0075","BK0057","000661","BK0046","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645873015","title":"股市必读:长春高新(000661)6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645873015","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645873015?lang=zh_cn&edition=full","pubTime":"2026-06-22 02:35","pubTimestamp":1782066917,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,长春高新报收于64.1元,上涨0.49%,换手率1.7%,成交量6.81万手,成交额4.38亿元。董秘最新回复投资者: 股价持续下跌,公司高层没有解决方案吗?长春高新信用目前处于哪一个等级。当日关注点交易信息汇总:6月18日主力资金净流出1520.79万元,散户资金净流入1947.18万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200000919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","000661","BK0046","BK0028","BK0188","BK0239","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645095479","title":"每周股票复盘:长春高新(000661)现1723.58万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2645095479","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645095479?lang=zh_cn&edition=full","pubTime":"2026-06-21 02:11","pubTimestamp":1781979070,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,长春高新(000661)报收于64.1元,较上周的66.5元下跌3.61%。本周,长春高新6月15日盘中最高价报66.39元。6月18日盘中最低价报63.01元,股价触及近一年最低点。长春高新当前最新总市值261.49亿元,在生物制品板块市值排名8/51,在两市A股市值排名834/5206。本周关注点交易信息汇总:6月15日长春高新现1723.58万元大宗交易交易信息汇总6月15日长春高新现1723.58万元大宗交易以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","BK0057","BK0239","BK0075","BK0028","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644770797","title":"长春高新:结缔组织病相关间质性肺病相关适应症处于临床阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2644770797","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644770797?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:18","pubTimestamp":1781767104,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月18日在投资者关系平台上答复投资者关心的问题。投资者提问:有研究证明,空气污染会引发一种名为白细胞介素-1β的信号分子的释放。当IL-1β到达携带休眠致癌突变的肺细胞时,会激活这些突变,细胞就会增殖并长成肿瘤,在暴露于空气污染的小鼠体内阻断IL-1β可阻止肿瘤形成,这为预防性药物的研发带来了希望。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800020889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0075","BK0046","BK0239","BK0028","000661","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644762770","title":"长春高新:未发现存在违规变相协助大股东化债的情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2644762770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644762770?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:18","pubTimestamp":1781767104,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司持续扩大支出资金几十亿,留给股东利润1.5个亿,请问巨额资金流向是否给实控人化债所用?长春高新回复:您好,上市公司与大股东之间有着严格的独立性要求,公司严格按照法律法规要求进行经营管理,严禁上市公司资金非经营性流向大股东。公司及会计师年审也会关注核验成本归集真实性及与大股东之间的资金往来情况,未发现存在违规变相协助大股东化债的情况。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800020888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0075","000661","BK0028","BK0057","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644702537","title":"长春高新:酒店项目于2025年6—7月相继正式开业运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2644702537","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644702537?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:12","pubTimestamp":1781766735,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司的投资十多亿的大酒店还在正常经营吗?长春高新回复:您好,酒店项目于2025年6—7月相继正式开业运营,并与洲际酒店集团专业管理团队合作,目前正常经营中,处于新开业初期的市场培育期,谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF责任编辑:陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800020792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0046","BK0239","BK0028","BK0188","000661","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644770103","title":"长春高新:公司经营管理层努力提升经营质量","url":"https://stock-news.laohu8.com/highlight/detail?id=2644770103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644770103?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:06","pubTimestamp":1781766380,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问:股价持续下跌,公司高层没有解决方案吗?长春高新回复:您好,公司经营管理层努力提升经营质量,加快产品研发、销售力度,希望以更好的业绩回报广大投资者。同时,公司未来若有达到信息披露要求的市值管理相关举措安排,将严格履行决策程序并及时对外披露。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800020746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0046","BK0028","BK0057","000661","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643527453","title":"6月15日长春高新现1723.58万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2643527453","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643527453?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:40","pubTimestamp":1781516400,"startTime":"0","endTime":"0","summary":"证券之星消息,6月15日长春高新发生大宗交易,交易数据如下:近三个月该股共发生2笔大宗交易,合计成交2592.0手,溢价成交2笔。该股近期无解禁股上市。截至2026年6月15日收盘,长春高新(000661)报收于65.52元,下跌1.47%,换手率2.28%,成交量9.11万手,成交额5.96亿元。该股最近90天内共有7家机构给出评级,买入评级5家,增持评级2家;过去90天内机构目标均价为105.68。本文数据来源于深圳证券交易所大宗交易信息披露,仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500022413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000661","BK0188","BK0046","BK0028","BK0057","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642637442","title":"长春高新最新公告:子公司注射用GenSci136获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2642637442","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642637442?lang=zh_cn&edition=full","pubTime":"2026-06-10 17:35","pubTimestamp":1781084157,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司子公司金赛药业收到国家药监局核准签发的《药物临床试验批准通知书》,注射用GenSci136境内生产药品注册临床试验申请获批,适应症为眼肌型重症肌无力。该药品为金赛药业自主研发的BAFF/APRIL双靶点拮抗剂,属治疗用生物制品1类。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000031090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0075","000661","BK0028","BK0057","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642414009","title":"长春高新:系统性推进市值管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2642414009","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642414009?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:35","pubTimestamp":1781062517,"startTime":"0","endTime":"0","summary":"董秘是否又在推动市值管理政策落地?长春高新回复:您好,公司充分重视市值管理工作,并持续通过强化核心竞争力、优化业务布局、完善投资者关系管理、进一步提升信息披露透明度等多方面举措,系统性地推进市值管理工作,致力于实现公司内在价值与市场价值的动态平衡,切实维护全体股东的长远利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000017419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0075","BK0057","BK0239","BK0046","BK0188","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642678416","title":"长春高新:公司全力聚焦医药创新与主业发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2642678416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642678416?lang=zh_cn&edition=full","pubTime":"2026-06-10 08:57","pubTimestamp":1781053033,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月10日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司会尽快剥离房地产业务吗?长春高新回复:您好,感谢您对公司的关注,,公司全力聚焦医药创新与主业发展,同时也正推进辅业轻资产转型;同时,未来地产板块如有其他达到信息披露标准的情况,公司会按照法律法规要求履行披露义务,谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000007776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0057","09939","BK0188","BK0239","BK0046","BK0075","BK1161","BK0028","000661","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642541662","title":"长春高新:产品临床试验获批相关公告是公司为了响应投资者所提出的希望公司持续提升信息披露透明度、增强投资者对于公司在研管线等情况了解的诉求进行的信息披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2642541662","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642541662?lang=zh_cn&edition=full","pubTime":"2026-06-10 08:54","pubTimestamp":1781052851,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月10日在投资者关系平台上答复投资者关心的问题。产品临床试验获批相关公告是公司为了响应投资者所提出的希望公司持续提升信息披露透明度、增强投资者对于公司在研管线等情况了解的诉求进行的信息披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000007740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","000661","BK0046","BK0028","BK0188","BK0239","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641668116","title":"长春高新:公司正处于从单一爆品向多元化创新的研发转型阵痛期","url":"https://stock-news.laohu8.com/highlight/detail?id=2641668116","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641668116?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:42","pubTimestamp":1780648935,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月05日在投资者关系平台上答复投资者关心的问题。(长春高新回复:您好,创新药从临床、准入、学术推广到真正放量,普遍需要多年培育期,必须持续投入才能形成壁垒。目前公司正处于从单一爆品向多元化创新的研发转型阵痛期,我们希望随着相关创新药后续逐步落地,能够使公司收获更多的研发成果,我们也将持续关注研发进展及费用支出情况,努力提升研发效率等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000661","BK0188","BK0075","BK0057","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641194819","title":"长春高新:公司此前向港交所提交的 H 股发行上市申请材料(A1 申请表)已超过港交所规定的六个月申报有效期","url":"https://stock-news.laohu8.com/highlight/detail?id=2641194819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641194819?lang=zh_cn&edition=full","pubTime":"2026-06-05 11:39","pubTimestamp":1780630764,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司去年计划在港交所上市,目前是什么情况呢?是计划已经取消,还是在持续推进?长春高新回复:您好,公司此前向港交所提交的 H 股发行上市申请材料(A1 申请表)已超过港交所规定的六个月申报有效期。公司将结合自身经营状况、监管政策要求及市场投资者关切,审慎、合理推进后续相关工作,具体时间需要结合工作进度和监管部门审核情况。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500015594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HEXmain","BK0057","BK0239","BK0028","BK0188","BK0075","000661","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783239938327,"stockEarnings":[{"period":"1week","weight":0.0981},{"period":"1month","weight":-0.0099},{"period":"3month","weight":-0.184},{"period":"6month","weight":-0.2534},{"period":"1year","weight":-0.3489},{"period":"ytd","weight":-0.2534}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0421},{"period":"6month","weight":0.0188},{"period":"1year","weight":0.1683},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"138133人(较上一季度增加7.70%)","perCapita":"2892股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":" 长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是注射用人生长激素、重组人生长激素注射液、注射用重组人促卵泡激素、重组人促卵泡激素注射液、醋酸曲普瑞林注射液、伏欣奇拜单抗、屋尘螨变应原制剂、醋酸甲地孕酮口服混悬液、口腔凝胶、水痘减毒活疫苗、带状疱疹减毒活疫苗、冻干鼻喷流感减毒活疫苗、鼻喷流感减毒活疫苗、银花泌炎灵片、清胃止痛微丸、血栓心脉宁片、疏清颗粒。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}